+ All Categories
Home > Documents > UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer...

UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer...

Date post: 09-Apr-2018
Category:
Upload: truongcong
View: 218 times
Download: 3 times
Share this document with a friend
16
Transcript
Page 1: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

I

Page 2: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

Arthur Ellis (Chair) Vice Chancellor, Research

Amy Alexander Associate Professor, Visual Arts

Michael Burkart Professor, Chemistry and Biochemistry

Linda Dale Assistant Vice Chancellor, Office of Contract and Grant Administration

Michael David Professor, Biology

Adriene Jenik Professor, Visual Arts

Steve Kay Dean, Division of Biological Sciences

Michael Kelner Professor, Pathology

William Kuperman Professor, Scripps Institution of Oceanography—Marine Physical Laboratory

Jane Moores Assistant Vice Chancellor, Technology Transfer

Rosibel Ochoa Executive Director, William J. von Liebig Center—Jacobs School of Engineering

Geert Schmid-Schoenbein Professor, Bioengineering

Frieder Seible Dean, Jacobs School of Engineering

Robert Sullivan Dean, Rady School of Management

UC San Diego Technology Transfer Advisory CommitteeThe UC San Diego Technology Transfer Advisory Committee (TTAC) is responsible for general oversight of the university’s technology transfer program. This standing committee is appointed and chaired by the vice chancellor for research. It meets quarterly to assess UC San Diego’s technology transfer practices and guide the overall direction of the program.

UC San Diego Industry Technology Transfer Advisory CommitteeThe UC San Diego Industry Technology Transfer Advisory Committee (I-TTAC) provides guidance, from an industry perspective, on university technology transfer and strengthens ties with our industry partners.

Julia Brown Member of board of directors: CONNECT, Labopharm, Inc., MediQuest Therapeutics, Inc., and Targacept, Inc.

Scott Minick President and CEO, BIND Biosciences (since January 2010) Venture Partner (Managing Director during FY2009), ARCH Venture Partners

Bob SlapinExecutive Director, San Diego Software Industry Council

Page 3: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

T echnology transfer plays a pivotal role in delivering new innovations to commercial markets and contributing to a vibrant economy. Despite a pervasive downturn in the

global economy, UC San Diego’s Technology Transfer Office (TTO) continues to leverage its resources by placing university technology into the capable hands of established and entrepreneurial businesses.

Last fiscal year, we managed innovation disclosures, patenting, and marketing activities for campus constituents and licensed technologies to both existing and start-up companies. Furthermore, for the first time since its inception, TTO surpassed the four-hundred mark in the number of innovation disclosures received and processed in a fiscal year period.

In addition, we continued to work with our business partners to weather a tough economic climate. Our investment of time and energy helps to yield products and technologies that have great potential to fuel the future growth of our region and contribute to the public good. To demonstrate this point, we added cumulative information in this report regarding the number of start-ups formed in the last decade using licensed UC San Diego technology.

To further enhance our relationships with corporate partners, an Industry Technology Transfer Advisory Committee was formed to serve as an interface between the university and the business sector. The TTO is working with this committee to explore new

and even more effective mechanisms to translate academic technologies into broader use by commercial entities. Each member was selected for their expertise in business areas that TTO targets for potential partnering opportunities.

In calendar year 2010, the university will celebrate its 50th Anniversary. In the short time since its founding in 1960, UC San Diego has been hailed for its academic and scientific achievements. While our technology transfer program is even younger by comparison, TTO has advanced rapidly in its mission to transfer technology by continuing to improve services and by cultivating relationships with campus and corporate partners. Reflecting the university’s vision, our licensing activities in San Diego and beyond have local impact, national influence, and global reach.

In this report we share our ongoing efforts to illustrate how university research translates into new jobs, technologies, products, and treatments that make our world a better place.

Sincerely,

Jane C. Moores, Ph.D. Assistant Vice Chancellor, Technology Transfer

Message from the Assistant Vice Chancellor

2009 Annual Report

Page 4: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

2

T he genesis of Otonomy was sparked by a trip to the emergency room in January 2008. Jay Lichter, a busy business executive and entrepreneur, had an otic (inner ear)

disorder that resulted in partial hearing loss six months previously. However, on this day, it was worse than usual. Suffering from an extended bout of vertigo, Lichter was scheduled for an audiology exam to be followed by a visit to an ear, nose, and throat (ENT) doctor. The ENT specialist was Dr. Jeffrey Harris, Chief of the Division of Otolaryngology, Head and Neck Surgery at UC San Diego, who diagnosed Lichter with Ménière’s disease, an inner ear disorder that affects hearing and balance and has no known or approved drug treatment.

The conversation between the two men evolved into a business discussion exploring alternate means of treating simple otic disorders—like hearing loss—and led to Lichter asking Harris about ideas for starting a new company. Lichter and Harris eventually arranged a meeting with Allen Ryan, professor of surgery at UC San Diego. Jointly the three men founded Otonomy, Incorporated and approached UC San Diego’s Technology Transfer Office to discuss licensing options in May 2008. The trio subsequently signed a license agreement in November 2008.

As cofounders and leaders on Otonomy's scientific advisory board, Harris and Ryan collaborated with the Otonomy science team. By the end of the fourth quarter of 2008, the group had developed the company’s first compound and had determined dosage proportionality in an animal model.

According to Lichter, “Our first product is a steroid to treat Ménière’s disease. We have a second product in the making that will be an antibiotic for middle ear infections.”

But Otonomy is not just about compound therapies. The company also devised an innovative delivery mechanism. Current conventions involve physicians injecting a solution into the middle ear, where it remains for barely an hour, then drains out. Otonomy’s delivery mechanism incorporates hydrogel technology. Using a small needle, physicians deliver the compound into the ear as a liquid that thickens when it reaches body temperature. The resulting pudding-

like substance provides sustained release of the compound for weeks and even months.

With its therapeutic approaches and innovative drug-delivery technologies, Otonomy is focused on treatments for several otic disorders: age-related hearing loss, noise-related hearing loss, Ménière’s disease, otitis media, tinnitus, and sudden and sensorineural hearing loss. While not life-threatening, these conditions decrease the quality of life for nearly 30 million Americans. The available solutions have been ineffective: oral antibiotics that treat a localized problem too broadly or direct-area solutions that drip down the Eustachian tube too quickly.

Future possibilities for treatment could reduce the risks of surgically implanted ear tubes in children. The new sustained-release gel could be injected during surgery for a one-time treatment that lasts for a week. Additionally, with a more effective direct-delivery mechanism, the new treatments may potentially reduce the use of resistance-causing oral antibiotics.

Otonomy, Inc.

Technology Transfer Office

Page 5: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

An ਞ-synuclein pore model of Parkinson’s disease.

3

I n 2007, UC San Diego researcher Dr. Eliezer Masliah (professor, neuroscience and pathology) announced a breakthrough discovery in the area of neurodegenerative disorders. The

discovery resulted from a collaborative effort between Masliah, Igor Tsigelny (researcher, neurosciences and San Diego Supercomputer Center), and Wolf Wrasidlo (researcher, Moores UCSD Cancer Center) and provides a new approach to the treatment of individuals diagnosed with Parkinson’s disease (PD), Alzheimer’s disease (AD), and other similar conditions.

The discovery was licensed the following year by a newly formed start-up venture—Neuropore Therapies, Incorporated. Formed in 2008, Neuropore advanced Masliah’s research and is developing and testing compounds that block the protein aggregates associated with these adverse neurological conditions.

The basis of Masliah’s research is centered on the premise that protein aggregates form abnormally in the brains of PD and AD patients, causing a neurologically toxic condition. More

specifically, the toxic aggregates—known as oligomers—penetrate an individual’s brain-cell membranes, causing impaired neuronal communication and functioning.

Neuropore Therapies’ approach is to develop proprietary small-molecule compounds that interfere with the formation of these alpha-synuclein (PD) and amyloid-beta (AD) oligomers. The compounds may offer promising alternatives to a medical community that has been able to offer only palliative treatments. Currently, PD affects about 6.3 million people and AD affects approximately 35 million people globally. The incidence of both diseases is expected to grow significantly as the population ages.

According to Masliah, who serves as a scientific and clinical advisor for Neuropore Therapies, the compounds will be ready for preclinical testing in 2010 and for phase I trials in the next couple of years.

Neuropore Therapies, Inc.

2009 Annual Report

Page 6: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

4

1 2 3 4

8765

11 129 10

I n FY2009 more than 60 companies and organizations offered over 200 products derived from UC San Diego innovations. The companies represent industry segments in biotechnology, consumer food additives, data storage, diagnostics, engineering equipment, genomics, pharmaceuticals, publishing, raw chemicals, research reagents and tools, software, structural materials, and wireless communications.

Our corporate partners play a major role in developing and advancing university innovation into commercial products. Some of the UCSD innovations were components of a commercial product and others were stand-alone materials, software, images, or therapeutics.

Products from University Innovation

Technology Transfer Office

(1) Cloud Condensation Nuclei (CCN) Counter is sold by Droplet Measurement Technologies to measure atmospheric particles. (2) The Ortiva Wireless mobile Video Optimization Gateway (mVOG™) is a server–based system that optimizes multimedia content for reliable delivery to mobile devices. (3) Fluorescent proteins are part of assay kits sold by several research reagent companies. (4) Pentosan polysulphate treats interstitial cystitis and is sold as Elmiron® by Ortho-McNeil-Janssen Pharmaceuticals, Inc. (5) ERBITUX® (cetuximab) is sold by ImClone Systems (a wholly-owned subsidiary of Eli Lilly and Company) and Bristol-Myers Squibb Company for the treatment of colorectal cancer and head and neck cancer. (6) CytoTrap is an assay used to study protein-to-protein interactions and is sold by Agilent Technologies-Stratagene Products. (7) Nirvana® SRB® Data Sharing, Metadata, and Advanced Data Management for Complex Environments is sold by Nirvana (a division of General Atomics). (8) Chromatin Assembly Kit is a research kit marketed by Active Motif. (9) Promega bioluminescent reagents are used worldwide for life science research and pharmaceutical discovery. (10) Senomyx, Inc. has product discovery and development collaborations with global food, beverage, and ingredient supply companies, some of which are currently marketing products that contain Senomyx’s flavor ingredients. (11) Marine-controlled source EM (CSEM) instrument surveys the seafloor for potential oil deposits. (12) Walrus Internet Graphic that shows network topology has been licensed to several publishers.

Page 7: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

Start-ups with Licensed UCSD Technology FY2000–2009

5

2009 Annual Report

Start-upsUC San Diego continues to be a magnet for stellar science and entrepreneurial culture; the creative talent on the campus triggers

the growth of new businesses in our region. Many current and former faculty members, staff members, alumni, and students have ventured forth to start new companies. While university affiliates have been credited with forming more than 200 start-up

companies, the Technology Transfer Office specifically tracks start-up companies with formal license agreements with the university for foundational technology, which number more than 130. The chart below illustrates the start-up activity for the Technology Transfer Office over the last decade. These companies were formed with one or more technologies licensed from TTO.

In FY2009, seven start-ups were formed with licensed university technology, compared to fourteen start-ups formed in the prior fiscal year. The decrease in the number of start-ups can be attributed to the collapse in the financial markets during this period. Venture firms and other investor groups significantly retreated from funding new businesses, preserving their capital in anticipation of an economic recovery. Two start-ups from the FY2009 group are highlighted in the preceding section.

Biomedical/Life Science

Engineering/Software/Physical Science

5

2

7

3

4

7

6

3

8

9

8

6

4

3

5

106

2

00 0201 04 06 08 090503 07

Total

Year

7

2

7 1011 9 17 14 7158 9

Page 8: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

6

Page 9: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

7

Page 10: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

8

Technology Transfer Agreements In FY2009, total agreement activity decreased to 697 compared to 796 during FY2008. The agreements comprised licenses, options, outgoing material transfers, confidentiality, letters of intent, and other administrative agreements. Much of the decrease can be attributed to reduced numbers of outgoing material transfer agreements.

The licensing activity for inventions was similar to last year: 42 invention licenses in FY2009 compared to 41 in FY2008. Copyright licensing decreased to 23 in FY2009 from 41 in FY2008.

00 03 0701 04 0802 0605 09

489

626

758

576

699

796

592

747713 697

2009 Results

License Agreements for Inventions and Copyrights FY2000–2009

Inventions

Copyrights/Trademarks

6

41

15

41

2328

17

54

34

12

41 41 42

49

222318

00 0402 0601 08 090503 07

56

29

Total

Year

47 5651 7146 82 657141 85

23

Page 11: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

9

PATENTS FILED 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 TOTAL

U.S. Provisional 55 74 75 127 144 133 147 142 127 152 1,176

U.S. Nonprovisional 87 76 86 45 44 39 35 65 85 73 635

International 22 40 41 69 94 67 89 60 53 61 596

Total Filed 164 190 202 241 282 239 271 267 265 286 2,407

PATENTS ISSUED 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 TOTAL

U.S. 58 59 42 51 50 60 44 64 45 54 527

Foreign 33 36 39 69 79 87 148 62 116 97 766

Total Issued 91 95 81 120 129 147 192 126 161 151 1,293

Patent Activities FY2000–2009

Patents Patent prosecution and protection of UC San Diego innovations continues to be a major component of our activities. In FY2009, 286 patent applications were filed, of which 225 were U.S. provisional and nonprovisional applications. The total number of filings in FY2009 increased from 265 patents filed in FY2008. Since FY2002, the campus has filed over 200 patent applications each fiscal year.

In FY2009, total issued patents decreased to 151 patents, as compared to 161 patents in FY2008. The number of U.S. patents issued increased to 54 patents in FY2009, as compared to 45 U.S. patents issued in FY2008. On average, it takes from three to five years for a U.S. patent to issue from the time an application is first examined at the U.S. Patent and Trademark Office.

Mandatory Distributions The Technology Transfer Office distributed approximately $15.1 million of intellectual property income in FY2009, compared to $14.8 million in FY2008. Distributions were made to inventors/authors, joint co-owners of IP, participating academic units for research support, the campus fund, and the UC General Fund in accordance with UC policies and UC San Diego campus guidelines. Invention and copyright income distributions are based on income received in the prior fiscal year (accrual basis). Material Transfer Agreement (MTA) income distribution is based on income received in the same fiscal year (cash basis).

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 TOTAL

Inventor/Author Share $1,598 $2,155 $2,098 $4,054 $2,654 $3,727 $6,192 $8,667 $8,605 $9,553 $49,303

Joint Titleholders Share $60 $197 $633 $304 $295 $77 $393 $127 $398 $432 $2,916

Research Labs/HAU*/Dept. Share $980 $929 $1,990 $1,271 $1,126 $1,215 $1,747 $2,501 $2,332 $2,516 $16,606

UC General Fund Share† $730 ($412) $1,519 ($1,219) $1,007 $2,657 $3,382 $2,612 $3,470 $2,569 $16,318

Total Distributions $3,368 $2,869 $6,240 $4,410 $5,082 $7,676 $11,714 $13,907 $14,806 $15,070 $85,142

*Home Academic Unit † FY01 and FY03 shows credit due to extraordinary legal expenses; formerly called State General Fund.Some totals may change from year to year due to post-closing adjustments.

Mandatory Distributions of IP Management Income FY2000–2009 (In Thousands)

Page 12: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

10

Intellectual Property Disclosures The number of invention and copyright disclosures reported to our office rose to 428 during FY2009, compared to 364 disclosures during FY2008. This is the first time that the campus surpassed the 400 mark in the number of disclosures received and processed in a fiscal year period. Since FY2002 the campus has achieved more than 300 disclosures per fiscal year. At the end of FY2009, the campus had more than 2,600 innovations in its portfolio.

Intellectual Property Income FY2000–2009 (In Millions)

Intellectual property income includes patent cost reimbursements and payments of fees and royalties from inventions, copyrights, and tangible research materials.

00 03 0701 04 0802 0605 09

$9.0$10.7

$26.2

$8.4

$15.1

$30.8

$17.0

$26.7

$21.7

$27.1

Total Intellectual Property Disclosures FY2000–2009

Copyrights Inventions

41

194

26

288

56

255

35

310

265

1634

330

396

32

290

44

294

28

333

40

Total

Year

235 314311 345281 364 428334322 373

00 0402 0601 08 090503 07

Page 13: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

11

INCOME

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 TOTAL

Invention $5,477 $5,627 $7,240 $6,368 $11,473 $15,496 $21,842 $21,423 $22,694 $22,235 $139,875

Copyright $84 $46 $203 $157 $314 $214 $311 $219 $317 $236 $2,101

Tangible Research Materials

$647 $595 $1,123 $474 $405 $578 $310 $329 $586 $255 $5,302

Legal CostReimbursement

$2,815 $2,032 $2,899 $3,678 $2,896 $5,396 $4,234 $4,080 $7,261 $4,397 $39,688

Extraordinary Income*

$33 $56 $5,552 – – – $1 $193 $23 – $5,858

Total Income $9,056 $8,356 $17,017 $10,677 $15,088 $21,684 $26,698 $26,244 $30,881 $27,123 $192,824

EXPENSE

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 TOTAL

Patent Prosecution

$3,503 $3,104 $3,833 $4,029 $4,645 $6,132 $6,161 $6,336 $7,126 $6,263 $51,134

Copyright $8 $5 $1 $3 – $4 – – – – $20

Campus Operations

$1,214 $1,386 $1,696 $1,981 $2,263 $2,272 $2,691 $2,732 $2,738 $3,077 $22,052

UCOP & OTT Assessment

$438 $603 $862 $902 $877 $892 $879 $461 $65 $65 $6,044

Extraordinary Expenses†

$221 $3,916 $2,993 $6,567 $2,789 $459‡ $57 $205 $18 $3 $17,228

UC General Fund**

$730 ($412) $1,519 ($1,219) $1,007 $2,657 $3,382 $2,612 $3,471 $2,569 $16,316

Total Expense $6,114 $8,602 $10,904 $12,263 $11,581 $12,416 $13,170 $12,346 $13,418 $11,977 $112,791

NET INCOME $2,942 ($246) $6,113 ($1,586) $3,507 $9,268 $13,528 $13,898 $17,463 $15,146 $80,033

*Extraordinary income includes nonrecurring items such as legal settlements and/or one-time payments. † Extraordinary expenses includes unbudgeted expenses for litigation and settlement. ‡ FY2005 extraordinary expenses increased by $201,000 from prior reports due to post-closing adjustments. **UC General Fund was previously called State General Fund.Some totals may change from year to year due to post-closing adjustments.

Income and Expenses FY2000–2009 (In Thousands)

The income and expense tables below provide detail on the sources of revenue received and expenses incurred in managing university technology.

Income In FY2009, intellectual property income was approximately $27.1 million, compared to approximately $30.9 million generated in FY2008. Income included nearly $22.2 million in license fees and royalties, which was down $460,000 from the previous year; $491,000 from fees for copyrights and transfers of tangible research materials, which was down $412,000 compared to the previous year; and approximately $4.4 million in patent cost reimbursement, down by about $2.9 million compared to the previous year.

Operating Expenses, Reimbursable Expenses, and DistributionsThe Technology Transfer Office incurred outlays of $12 million in FY2009, as compared to $13.4 million in the previous year. The decrease was attributed to lower patent prosecution costs of $6.3 million in FY2009, versus $7.1 million in the previous year and lower contributions to the UC General Fund for $2.6 million in FY2009, as compared to $3.5 million in the previous year. Campus operations costs were up slightly to $3.1 million in FY2009, compared to $2.7 million in the previous year.

Page 14: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

12

T he Technology Transfer Office attends, supports, participates in, or organizes various events throughout the year to promote technology transfer and university research.

July 08CONNECT Frontiers in Science —Planning Session*

Global CONNECT—South Korea Economic Development

Technology Exchange*

Tech Trek, American Association of University Women—Science and Math

Outreach Program for Middle School Girls*

Technology Showcase at the von Liebig Center

Panel Discussion: Explaining University Technology Transfer to Industry*

CONNECT Frontiers in Science and Technology—Protein Networks

in Cancer

August 08Translational Oncology Symposium—Moores UCSD Cancer Center

CONNECT Industry Advisory Committee*

Licensing Executive Society (LES) San Diego Chapter Meeting

UC Technology Transfer Office Directors’ Meeting—Oakland, CA

September 08Entrepreneurial Seminar—von Liebig Center

Tech Transfer at UCSD Seminar, Division of Biological Sciences*

Licensing Executive Society (LES) San Diego Chapter Meeting

UC Discovery Fellows—University Technology Transfer*

Connect with CONNECT

UC Technology Transfer Advisory Committee—Oakland, CA

California Institute for Regenerative Medicine (CIRM)—Online Q&A with

California Stem Cell Researchers

Licensing Executive Society (LES) Workshop—University and

Industry Relations*

Cleantech Presentations—von Liebig Center

Engineering in Medicine (EngMed)

San Diego Daily Transcript Biotech Roundtable

New IP Models for Industry—UCSD External Relations*

UCSD Department of Bioengineering—Industry Advisory Board*

October 08Licensing Executive Society (LES)—Standards, Admissions, and

Recertification Committee*

Patents and Patent Searching—UCSD Staff Education and

Development Workshop*

Innovators Roundtable Meeting—Physical Sciences Presentation*

Center for Magnetic Recording Research (CMRR) Review Meeting

CONNECT Venture Roundtable*

4th Modern Drug Discovery and Development Summit—

University/Industry Partnering*

Licensing Executive Society (LES) Annual Meeting—Orlando, FL

University Licensing: Opportunities and Issues—UCSD Department

of Bioengineering*

Consultants Forum Annual Meeting

BIOCOM Investor Conference

Cleantech Initiative Awards

November 08Technology Transfer Presentation—UCSD Department of Bioengineering*

CommNexus San Diego

Innovators Roundtable Meeting—Life Sciences Presentations*

Entrepreneurial Seminar—von Liebig Center

4th Annual SABPA Pacific Forum on Life Science Alliances

BIOCOM Breakfast—Algae Biofuels

CONNECT Technology Transfer Roundtable

Analytics in Marketing, Healthcare, Mobile Analytics, and Energy

UC Intellectual Property Managers—Santa Barbara, CA*

Institute for Conservation Research—Starting a Technology

Transfer Program*

December 08UCSD Business and Financial Services Purchasing Managers*

Technology Licensing from TTO and Entrepreneur Viewpoints—

San Diego State University, School of Business*

Entrepreneurial Seminar—von Liebig Center

Technology Transfer at UC San Diego—Skaggs School of Pharmacy and

Pharmaceutical Sciences*

Patents and Patent Searching—UCSD Staff Education and

Development Workshop*

CONNECT Most Innovative Product Awards and Program

January 09CONNECT Technology Transfer Roundtable

The Convergence of Nanotech and Cleantech Workshop—Palm Springs, CA*

UCSD Industry Technology Transfer Advisory Committee Meeting*

BIOCOM Breakfast—Corporate Investing

UCSD Department of Bioengineering—Industry Advisory Board*

Community Outreach and Partnering Events

Technology Transfer Office

Page 15: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

Representatives from the Canadian government

and POLE (an economic development agency) visit TTO.

[Left to right: Cheryl Rogers, Charles Gauthier, Denise Lew (TTO), Isabelle Genest, Yahya

Baby, and Claude Racine.]

13

February 09Licensing Executive Society (LES) San Diego Chapter Meeting

Association of University Technology Managers Annual Meeting—Orlando, FL*

TTO Overview and IP Process—Department of Chemistry and Biochemistry*

Patents and Patent Searching—UCSD Staff Education and

Development Workshop*

UC Technology Transfer Office Directors’ Meeting—Oakland, CA

Cancer Center Symposium—Moores UCSD Cancer Center

Research Expo—Jacobs School of Engineering

March 09Innovators Roundtable Meeting—Life Science Technology Presentations*

Technology Licensing from the TTO and Entrepreneur Viewpoints—

San Diego State University, School of Business*

UC Technology Transfer Advisory Committee—Oakland, CA

Kauffman Symposium—What Industry Wants from Universities

San Diego Center for Molecular Agriculture Symposium

April 09UC San Diego Communications Directors*

Material Transfer Agreements Workshop—Calit2*

Licensing Executive Society (LES) San Diego Chapter Meeting

May 09California Clean Innovation 2009 Conference*

BIOCOM Breakfast—Ernst & Young Industry Report

Thinking Outside the Petri Dish—UCSD Biological Sciences

Student Association*

Patents and Patent Searching—UCSD Staff Education and

Development Workshop*

Entrepreneurial Seminar—von Liebig Center—Intellectual Property

Presentation*

Technology Transfer for the Rady Student—UCSD Rady School

of Management*

Association for Women in Science (AWIS)*

UC Intellectual Property Managers—Oakland, CA*

Licensing Executive Society (LES) San Diego Chapter Meeting—The Future

of Biotech: How to Succeed in a Time of Change

UC San Diego Salute to Innovation Program and Reception*

BIO 2009 International Convention—Atlanta, GA

June 09Emerging Trends in Intellectual Property Valuation and Risk Analysis

8th Annual SABPA Symposium on Biopharmaceuticals

Licensing Executive Society (LES) San Diego Chapter Meeting— The New

Era: Personalized Medicine

Global CONNECT—Southampton (UK)/San Diego Cleantech Conference

Genome Frontiers Symposium

The Technology Transfer Office met with various organizations throughout the year for benchmarking technology transfer activities and to share best practices in technology transfer and economic development.

July 08Global CONNECT—Memorial Health System

September 08 University of Manchester, England

November 08Global Leadership Institute (GLI)—Shanghai Huangpu District Delegation

December 08 POLE Quebec Economic Development Agency, Canada

Osaka University, Japan

January 09Jiangsu Province Biotechnology District, China

March 09Japan Patent Office

University of Melbourne, Australia

June 09A*STAR and Exploit, Singapore

Visitors 2008–2009

*TTO staff presented or actively participated.

Page 16: UC San Diego Technology Transfer Advisory Committee Annual... · UC San Diego Technology Transfer Advisory Committee ... nose, and throat (ENT) ... n 2007, UC San Diego researcher

University of California, San Diego | 9500 Gilman Drive # 0910 | La Jolla, CA 92093-0910

(858) 534-5815 | invent.ucsd.edu

0910-124

Technology Transfer Office


Recommended